eli lilly retatrutide study Lilly's Phase 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Lilly's triple agonist delivers up

Still, the benefits and risks of bariatric surgery are well-documented, with proven long-term health improvements

Is your appetite truly out of control

When it comes to weight management, GLP-1s natural ability to reduce appetite and support blood sugar regulation can make it highly effective

June 2026 update: FDA issues 25 more warning letters to telehealth companies During the week of June 15, 2026 - days before this article was published - the FDA issued 25 additional warning letters to telehealth companies over false or misleading promotional claims about compounded GLP-1 products

Across pivotal Phase 3 trials, mean weight loss has scaled with the number of receptors a compound engages: semaglu tide (single agonist) at 14.9%, tirzepatide (dual agonist) at 22.5%, and retatrutide (triple agonist) at 28.3% over 80 weeks

M., Ma, X